UK Haemophilia Centre Doctors’ Organisation guidance on the use of extended‐half‐life coagulation factor concentrates in routine clinical practice: Report of a meeting on their adoption by Belgian haemophilia treaters

Hermans, Cédric; Damme, An Van; Dolan, G.; Maes, Philip; Peerlinck, Kathelijne

doi:10.1111/hae.13593

Haemophilia

2018

DOI: 10.1111/hae.13593

|View full text |Cite

UK Haemophilia Centre Doctors’ Organisation guidance on the use of extended‐half‐life coagulation factor concentrates in routine clinical practice: Report of a meeting on their adoption by Belgian haemophilia treaters

Cédric Hermans¹,

An Van Damme²,

G. Dolan

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2018

2021

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, mental nursing should continue throughout the hospitalization period. The Hospital Anxiety and Depression Scale (HADS) 14 injection. Because the surgical razor is not available for preoperative skin preparation, depilatory paste is an alternative after the absence of an anaphylactic reaction has been confirmed in a nonoperative area.…”

mentioning

confidence: 99%

Application of optimized nursing process to perioperative patients with haemophilic pseudotumours

Chen

Zhou

et al. 2018

Haemophilia

View full text Add to dashboard Cite

mentioning

confidence: 99%

Application of optimized nursing process to perioperative patients with haemophilic pseudotumours

Chen

Zhou

et al. 2018

Haemophilia

View full text Add to dashboard Cite

Current and Future Options of Haemophilia A Treatments

Miesbach

Eladly²

2021

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

Treatment Options in Hemophilia

Miesbach¹,

Schwäble²,

Müller³

et al. 2019

Deutsches Ärzteblatt International

View full text Add to dashboard Cite

Key messages• Standard treatment for hemophilia consists of prophylactic administration of a coagulation factor concentrate. This must be performed several times a week (intravenously).• Long-acting coagulation factor drugs can lengthen the time between treatments or increase coagulation factor levels.• New treatment options are based on new mechanisms of action and can be administered subcutaneously, sometimes with an extended half-life and a broad spectrum of application for hemophilia A, hemophilia B, and inhibitor hemophilia.• Emicizumab, which has already been authorized for use in Germany, significantly reduced hemorrhage rates in patients with hemophilia A, regardless of inhibitor status.• Long-term safety data and data on concomitant use of factor or bypass concentrates are still pending.• Clinical trials of gene therapy have been successful for both hemophilia A and hemophilia B. In some cases, normal coagulation factor levels have been achieved.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

UK Haemophilia Centre Doctors’ Organisation guidance on the use of extended‐half‐life coagulation factor concentrates in routine clinical practice: Report of a meeting on their adoption by Belgian haemophilia treaters

Cited by 3 publications

References 6 publications

Application of optimized nursing process to perioperative patients with haemophilic pseudotumours

Application of optimized nursing process to perioperative patients with haemophilic pseudotumours

Current and Future Options of Haemophilia A Treatments

Treatment Options in Hemophilia

Contact Info

Product

Resources

About